KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015

Abstract

RAS mutations outside exon 2 of KRAS should be included in routine practice, since they predict also response to anti-EGFR. That would make certain these patients benefit from appropriate testing and treatment. In addition unjustified expenses of anti-EGFR targeted therapy could be avoided.